

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

JONES, Stephen, Anthony
AdamsonJones
Broadway Business Centre
32a Stoney Street
Nottingham NG1 1LL
ROYAUME-UNI

Date of mailing (day/month/year) 24 January 2002 (24.01.02)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 1060/363/P/WO	
International application No. PCT/EP00/08729	International filing date (day/month/year) 07 September 2000 (07.09.00)

1. The following indications appeared on record concerning:		
<input type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input checked="" type="checkbox"/> the agent
<input type="checkbox"/> the common representative		
Name and Address THACKER, Michael, Anthony Group Patents Dept (D31) 1 Thane Road West Nottingham Nottinghamshire NG2 3AA United Kingdom	State of Nationality	State of Residence
	Telephone No. +44-115-959-4544	
	Facsimile No. +44-115-959-4599	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input checked="" type="checkbox"/> the name	<input checked="" type="checkbox"/> the address
<input type="checkbox"/> the nationality		
<input type="checkbox"/> the residence		
Name and Address JONES, Stephen, Anthony AdamsonJones Broadway Business Centre 32a Stoney Street Nottingham NG1 1LL United Kingdom	State of Nationality	State of Residence
	Telephone No. 01 15 9247147	
	Facsimile No. 01 15 9247148	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Jaime LEITAO
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 15 May 2001 (15.05.01)	
International application No. PCT/EP00/08729	Applicant's or agent's file reference P/695
International filing date (day/month/year) 07 September 2000 (07.09.00)	Priority date (day/month/year) 09 September 1999 (09.09.99)
Applicant PYKETT, Melanie, Ann et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 30 March 2001 (30.03.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).


The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Catherine Massetti Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P/695	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/08729	International filing date (day/month/year) 07/09/2000	Priority date (day/month/year) 09/09/1999
International Patent Classification (IPC) or national classification and IPC A61K7/42		
Applicant THE BOOTS COMPANY PLC		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 2 sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application 		
Date of submission of the demand 30/03/2001	Date of completion of this report 02.01.2002	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Szarek, S Telephone No. +49 89 2399 8219	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/08729

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-53 as originally filed

Claims, No.:

1-10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☒ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/08729

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)
see separate sheet

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	
	No: Claims	1-10
Inventive step (IS)	Yes: Claims	
	No: Claims	1-10
Industrial applicability (IA)	Yes: Claims	1-10
	No: Claims	

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

I

The amendments filed with the letter dated 14.08.2001 introduce subject-matter which extends beyond the content of the application as filed, contrary to Article 34(2)(b) PCT. The amendments concerned are the following:

Claim 1

The disclaimer "provided that the mixture does not contain a combination of ginseng, morus alba and grape seed oil" does not meet the requirements of Article 34(2)(b) PCT. This disclaimer does not exclude exactly the disclosure which is novelty destroying (WO 00/64278, examples 7 and 8).

**THEREFORE, THIS REPORT HAS BEEN ESTABLISHED ON THE ORIGINAL
CLAIMS 1-10 AS FILED (RULE 70.2 (c) PCT).**

V

Reference is made to the following documents:

D1 : JP-A-100195434
D2 : WO-A-9933439
D3 : US-A-5 084 289
D4 : WO-A-9833494
D5 : US-A-5 314 686

1. The present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 1-10 is not new.

Claim 1

Topical cosmetic compositions as defined in claim 1 are disclosed in :

D1 : this document discloses antioxidant compositions for use in cosmetics, which comprise a combination of rosemary extract, tocopherol concentrate and higher fatty acid ascorbate. The antioxidant is described to be synergetic.

D2 : page 6, l. 3 to 26; page 7, l. 4 to 6; page 9, l. 19 to 21; page 10, l. 3 to 5; examples 3 to 13; claims 53, 54, 56 and 57.

D3 : col. 2, l. 3 to 9; claims 4, 13, 15, 17 and 18. The use of a mixture comprising ascorbic acid, rosemary extract and tocopherol as antioxidant in cosmetic compositions is disclosed.

D4 : Formulas IIE, IIF and IIG (page 9) disclose wound healing compositions in the form of ointments (page 2, l. 30-31) comprising grape seed extract, vitamin C and ginkgo biloba. Formula IIIC, IIIE and page 3, l. 4-5.

2. Inventive step (Article 33 (3) PCT) can only be established on claims which are novel.
3. Claims 2-10
It appears that the additional technical features of the dependant claims would not render these claims novel or inventive over the prior art.

VI

Document WO 00/64278 discloses topical cosmetic compositions as claimed in examples 7 and 8.

VIII

1. According to the wording of claim 1 combinations of (a), (b) and (c) have to be formed to obtain the desired synergistic mixture. However, this is in contrast to the dependant claims and the description. Thus, the applicant is requested to reword Claim 1 in order to clearly show that any combination of ingredients is meant.
2. Superfluous expressions like "non-limiting" on page 10 should be deleted.
3. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1-D5 is not mentioned in the description, nor are these documents identified therein.

SKINCARE COMPOSITION AGAINST FREE RADICALS

5 The present invention relates to skincare compositions providing enhanced protection for the skin against free-radicals.

10 As we age, our skin undergoes changes such as becoming thinner, more easily damaged and less elastic. In addition, lifetime exposure to UVA and UVB radiation, together with other environmental pollution from traffic fumes, ozone, cigarette smoke etc, cause additional changes to the skin. These changes, such as lines and wrinkling, actinic lentigines, dyspigmentation, rough skin, actinic telangiectasia and further loss of skin elastic function are due to direct UV mediated damage to cells and indirectly mediated damage caused by the generation of free radicals in cells and tissues. This is generally termed photoageing and can account for up to 90% of the skin changes we associate with ageing.

20 Due to the major impact photoageing has on skin appearance and function, there has been much research conducted to develop technologies which can prevent the effects and help to repair existing damage.

To prevent sunlight mediated damage of skin cells and associated damage due to sunlight initiating the formation of free radicals in the skin, compositions containing a sunscreen may be used. These compositions generally contain an inorganic sunscreen such as titanium dioxide which reflects the sun's rays, or one or more of an organic sunscreen which absorbs the rays. A further measure to protect the skin is to use compositions containing antioxidants which act as free radical quenchers. These react with the free radicals and so terminate the chain of reactions that free radicals customarily propagate which so damage the skin.

30

Compositions containing sunscreens are known. Some sunscreen formulations also contain antioxidants. There are also cosmetic compositions, not containing sunscreens, which contain antioxidants for additional skin care and protection.

There are a number of skincare compositions, commercially available, which seek to minimise the damage to the skin by the inclusion of certain agents. In particular materials such as vitamins and herbal extracts have widely been known to reduce the formation of free-radicals. However to achieve good efficiency high levels of these materials have to be used and this can result in dark aesthetically unpleasing products.

The skincare compositions of the present invention have been shown to protect the skin more effectively from free radicals and are cosmetically and aesthetically more suitable than known skin care compositions. Therefore the skincare compositions of the present invention may be used to provide improved protection against damage to skin caused by exposure to factors such as sunlight, environmental and/or atmospheric pollution.

Therefore broadly according to the present invention there is provided a cosmetic composition suitable for application to the skin containing a combination of antioxidant ingredients that when combined together give a synergistic improvement in activity allowing improved protection to be provided for the skin without the drawback of aesthetically unpleasant product appearance.

The present invention provides cosmetic compositions suitable for application to the skin containing a synergistic mixture of three antioxidants in combination with a cosmetically acceptable diluent or carrier. The antioxidant agents used in the present invention are already known for their ability to quench free radicals and prevent oxidative damage to the skin. However the present invention discloses that certain combinations of these agents have a greater efficacy than that expected. This has been demonstrated by both *in vivo* and *in vitro* testing.

Suitable antioxidant agents may include:

- a) ascorbic acid its salts, esters, glucosides and glucosamines, particularly sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl palmitate
- b) vitamin E (tocopherol) and its esters, particularly tocopheryl acetate
- 5 c) herbal extracts, particularly ginkgo biloba, such as that available under the trade name "Ginkgo Biloba Leaf Powder" from Univar PLC, morus alba, such as that available under the trade name "Mulberry Concentrate" from Aston Chemicals, organum vulgare, such as that available under the trade name "Pronalen Organum HSC" from S Black Ltd, panax ginseng, such as that available under the trade name "Panax ginseng 1.1 extract 4294" from S Black Ltd or "Phytexcell Panax ginseng" available from Croda Chemicals Ltd, birch extract such as those available from Cosmetochem (U.K.) Ltd under the trade names "Super Herbasol Extract Birch" and "HP Herbasol Betula" and those available from Blagden Chemicals under the tradenames
- 10 "Phytelene of Birch" and "Aqueous Spray Dried Birch", camellia sinensis, such as that available under the trade name "Herbal Extract Green Tea 75% Solids" from Nichimen Europe, rosmarrinus officinalis such as that available under the trade name "Pronalen Rosemary" from S.Black, Acerola cherry powder such as that available as Acerola PE from Gee Lawson and
- 15 Grape Seed oil such as that available from Chesham Chemicals Limited.
- 20

The source of the antioxidant activity in some of these products is often not fully understood; for example, it is believed that the antioxidant activity of ginkgo biloba extract arises from the presence of flavonglycocides and/or

25 terpenelactones which may be free-radical inhibitors. Birch extract may be produced by extracting the dried leaves of Betula alba with a suitable solvent. It is believed that the anti-free radical activity of birch extract arises due to the presence of flavonoids such as hyperosid, quercitrosid and/or myricetol-3-digalactosid which may be free-radical inhibitors. Such products are then often

30 sold as mixtures or solutions.

Thus the antioxidant agent may consist of a number of active ingredients which

are free-radical inhibitors or may also comprise suitable diluents and/or carriers (such as when the anti-free radical agent is some of the products mentioned herein). Thus there may be some confusion as to the actual level of agent within a commercially available product. Accordingly, the amounts of antioxidant agents used in the present invention are expressed as dry weights, as understood by a man skilled in the art.

The total amount of antioxidant agents present in the composition may range from 0.005% to 10% by weight, preferably 0.5% to 5%, most preferably 1% to 3.5% by weight of the composition.

Particularly preferred synergistic combinations of antioxidant agents suitable for inclusion in a skin care composition of the present invention are:
panax ginseng, morus alba and magnesium ascorbyl phosphate;
panax ginseng, morus alba and sodium ascorbyl phosphate;
panax ginseng, morus alba and rosmarinus officinalis;
panax ginseng, morus alba and organum vulgare.

In these preferred combinations (a) the panax ginseng is preferably present in an amount of 0.005 to 0.1%, more preferably 0.01 to 0.05%, most preferably about 0.03% by weight of the composition; (b) the morus alba is preferably present in an amount of 0.0005 to 0.01%, more preferably 0.001 to 0.005%, most preferably about 0.0023% by weight of the composition; (c) the sodium or magnesium ascorbyl phosphate is preferably present in an amount of 0.05 to 2.5%, preferably 0.1 to 2%, most preferably 0.15 to 1.5% by weight of the composition and (d) the rosmarinus officinalis or organum vulgare is preferably present in an amount of 0.01 to 0.5%, more preferably 0.05 to 0.2%, most preferably about 0.1% by weight of the composition.

Suitable cosmetic compositions include colour cosmetics such as lipsticks, foundation, lip balm, face cream, toner cleanse, aftersun, moisturiser, face masks and nail treatments. Suitable formulation types include gels, creams,

serums, pastes, lotions, milks, ointments, salves, sticks, spray, roll-on, powder, solution, suspension dispersion and emulsions, be they w/o, o/w, w/o/w or o/w/o.

- 5 A particularly preferred cosmetic composition is a sunscreen.

The sunscreen may contain organic or inorganic sun filters or a combination of the two. Suitable inorganic sunfilters include:

- 10 a) Microfine titanium dioxide
 b) Microfine zinc oxide
 c) Boron nitride

Suitable organic sunscreens include:

- 15 a) p-aminobenzoic acids, their esters and derivatives (for example, 2-ethylhexyl p-dimethylaminobenzoate),
 b) methoxycinnamate esters (for example, 2-ethylhexyl p-methoxycinnamate, 2-ethoxyethyl p-methoxycinnamate or α,β -di-(p-methoxycinnamoyl)- α' -(2-ethylhexanoyl)-glycerin,
20 c) benzophenones (for example oxybenzone),
 d) dibenzoylmethanes such as 4-(tert-butyl)-4'-methoxydibenzoylmethane,
 e) 2-phenylbenzimidazole-5 sulfonic acid and its salts,
 f) alkyl- β,β -diphenylacrylates for example alkyl α -cyano- β,β -diphenylacrylates such as octocrylene,
25 g) triazines such as 2,4,6-trianilino-(p-carbo-2-ethyl-hexyl-1-oxi)-1,3,5 triazine,
 h) camphor derivatives such as methylbenzylidene camphor

Any sunscreening agent is present in an amount from 0.1 to 10% by weight of the composition.

30

Sunscreen composition may be formulated as any suitable form, as known to a man skilled in the art. Particularly preferred formulation types are emulsions

and oily dispersions.

5 A skin care composition containing a synergistic combination of antioxidant agents has a multitude of advantages. Such antioxidant agents are usually highly coloured. If they are used in amounts necessary to be totally effective, it is likely that the agents would give the composition a cosmetically unacceptable appearance. Thus most conventional skin care compositions use less of an antioxidant agent than necessary to provide total protection. With the present invention because of the increased efficacy of the synergistic mixture of
10 antioxidant agents it is possible to include the antioxidant agents in sufficient amounts to provide an effective defence against the action of free radicals. Thus use of the composition will give the users' skin improved protection from damage. All this is provided without the aforementioned disadvantage of unacceptable cosmetic appearance.

15 Alternatively, if the same level of protection as a conventional formulation is required, then the increased efficacy of the synergistic mixture of antioxidant agents means that the composition will require much lower quantities of the antioxidant agents than a conventional formulation. Not only are any problems
20 with highly coloured formulations reduced (cosmetic appearance), but the cost of the formulation is likely to be cheaper as well.

Further components may be added to the skin care composition as is well-known to those skilled in the art.

25 Suitable oils for the oil phase of the oily dispersions and the oil phase of the water-in-oil and oil-in-water emulsions of the present invention may comprise for example:

- a) hydrocarbon oils such as paraffin or mineral oils;
- b) waxes such as beeswax or paraffin wax;
- 30 c) natural oils such as sunflower oil, apricot kernel oil, shea butter or jojoba oil;
- d) silicone oils such as dimethicone, cyclomethicone or cetyldimethicone;
- e) fatty acid esters such as isopropyl palmitate or isopropyl myristate;

- f) fatty alcohols such as cetyl alcohol or stearyl alcohol; or
- g) mixtures thereof, for example, the blend of waxes available commercially under the trade name Cutina (Henkel).

5 The emulsifiers used may be any emulsifiers known in the art for use in water-in-oil or oil-in-water emulsions. It has been found that particularly effective water-in-oil and oil-in-water sunscreen compositions can be prepared by using an emulsifier or mixture of emulsifiers selected from known cosmetically acceptable emulsifiers which include:

- 10 a) sesquioleates such as sorbitan sesquioleate, available commercially for example under the trade name Arlacel 83 (ICI), or polyglyceryl-2-sesquioleate;
- b) ethoxylated esters of derivatives of natural oils such as the polyethoxylated ester of hydrogenated castor oil available commercially for example under
15 the trade name Arlacel 989 (ICI);
- c) silicone emulsifiers such as silicone polyols available commercially for example under the trade name ABIL WS08 (Th. Goldschmidt AG);
- d) anionic emulsifiers such as fatty acid soaps e.g. potassium stearate and fatty acid sulphates e.g. sodium cetostearyl sulphate available commercially
20 under the trade name Dehydag (Henkel);
- e) ethoxylated fatty alcohols, for example the emulsifiers available commercially under the trade name Brij (ICI);
- f) sorbitan esters, for example the emulsifiers available commercially under the trade name Span (ICI);
- 25 g) ethoxylated sorbitan esters, for example the emulsifiers available commercially under the trade name Tween (ICI);
- h) ethoxylated fatty acid esters such as ethoxylated stearates, for example the emulsifiers available commercially under the trade name Myrj (ICI);
- i) ethoxylated mono-, di-, and tri-glycerides, for example the emulsifiers
30 available commercially under the trade name Labrafil (Alfa Chem.);
- j) non-ionic self-emulsifying waxes, for example the wax available commercially under the trade name Polawax (Croda);

- k) ethoxylated fatty acids, for example, the emulsifiers available commercially under the trade name Tefose (Alfa Chem.); or
- l) mixtures thereof.

5 For example, preservatives may be added to the composition such as 2-bromo-2-nitropropane-1,3-diol (bronopol, which is available commercially under the trade name Myacide RTM), benzyl alcohol, diazolidinyl urea, imidazolidinyl urea, methyl paraben, phenoxy ethanol, propyl paraben, sodium methyl paraben, sodium dehydroacetate, polyhexamethylenebiguanide hydrochloride, 10 isothiazolone and sodium propyl paraben, suitably in an amount of from about 0.01% to about 10% by weight of the composition.

Thickeners, viscosity modifying agents and/or gelling agents may be added to the composition, such as acrylic acid polymers e.g. available commercially 15 under the trade name Carbopol (B.F. Goodrich) or modified celluloses e.g. hydroxyethylcellulose available commercially under the trade name Natrosol (Hercules) or hydroxypropylmethyl cellulose, amine oxides, block polymers of ethylene oxide and propylene oxide (for example, those available from BASF Wyandotte under the trade name "Pluronic" RTM), PVM, MA, or a decadiene 20 crosspolymer (available under the trade name Stabirez 60), ethoxylated fatty alcohols, salt (NaCl), phthalic acid amide, polyvinyl alcohols, fatty alcohols and alkyl galactmanans available under the trade name N-Hance from Hercules, suitably in an amount of from about 0.5% to about 10% by weight of the composition.

25 Sequestering agents may be added to the composition, such as ethylenediamine tetraacetic acid and salts thereof, suitably in an amount of from about 0.005% to about 0.5% by weight of the composition.

30 The composition may also include vitamins such as biotin, suitably in an amount of from about 0.01% to about 1.0% by weight of the composition.

The composition may also include waxes such as cocoa butter suitably in an amount of from about 1% to about 99% by weight of the composition.

5 The composition may also comprise suitable, cosmetically acceptable diluents, carriers and/or propellants such as dimethyl ether.

10 The composition may also include pearlising agents such as stearic monoethanolamide, suitably in an amount of from about 0.01% to about 10% by weight of the composition.

15 Perfumes may be added suitably in an amount of from about 0.01% to about 2% by weight of the composition, as may water soluble dyes such as tartrazine, suitably in an amount of from about a trace amount (such as 1×10^{-5} %) to about 0.1% by weight of the composition.

20 The composition may also include pH adjusting agents such as sodium hydroxide, aminomethyl propanol, triethanolamine, suitably in an amount of from about 0.01% to about 10% by weight of the composition.

25 The composition may be buffered by means well known in the art, for example by use of buffer systems comprising succinic acid, citric acid, lactic acid, and acceptable salts thereof, phosphoric acid, mono- or disodium phosphate and sodium carbonate. Suitably, the composition may have a pH between about 3 and about 10, preferably between about 4 and about 8.

30 The compositions of the present invention may additionally comprise other components which will be well known to those skilled in the art. These include, for example, emollients such as isopropyl myristate or triglycerides of fatty acids e.g. lauric triglyceride or capric/caprylic triglyceride, such as the triglyceride available commercially under the trade name Migliol 810 (Huls UK); moisturisers such as D-panthenol; humectants such as glycerin or 1,3-butylene glycol; antioxidants such as DL- α -tocopherylacetate or butylated

hydroxytoluene; emulsion stabilising salts such as sodium chloride, sodium citrate or magnesium sulphate; film formers to assist spreading on the surface of the skin such as alkylated polyvinylpyrrolidone e.g. available commercially under the trade name Antaron (GAF) and colourings.

5

Broadly in accordance with a further aspect of the present invention there is provided a method of preparing a skin care composition. Optionally any other suitable ingredients may be added such as those described herein. Preferred methods of preparation are described in the examples.

10

The invention will be understood with reference to the non-limiting tests and formulation examples described hereinafter:

Example 1 – Aftersun Treatment lotion

15

	%w/w
Aqua	to 100
Hydrated silica	5
Isopropyl palmitate	4
20 Arachidyl propionate	2
Dimethicone	2
Glycerin	2
Steareth-21	1.96
Steareth-2	1.683
25 Cetyl alcohol	1
Tribehenin	1
Glyceryl stearate	1
Paraffinum liquidum	0.994
Panthenol	0.75
30 Parfum	0.3
Xanthan gum	0.3
Sodium citrate	0.25

- 11 -

	Tocopheryl acetate	0.2
	Hydroxyethylcellulose	0.1
	Bisabolol	0.095
	Citric acid	0.05
5	Preservative	q.s
	Sodium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03

10 Method

Stage 1

The citric acid, sodium citrate and hydroxyethylcellulose are added to the water. Using a propellor stirrer, the mixture is stirred until dispersed. The xanthan gum
 15 is pre-dispersed in the glycerin and this is then added to the bulk, which is then heated to 70°C.

Stage 2

The isopropyl palmitate, arachidyl propionate, dimethicone, steareth-21,
 20 steareth-2, cetyl alcohol, tribehenin, glyceryl stearate, paraffinum liquidum are mixed and heated to 70°C to melt the waxes.

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and is mixed until emulsified and uniform. The emulsion is cooled to below 35°C using stirring. Once below
 25 35°C, the remaining materials are added, including the antioxidant complex. The product is made to weight using purified water, and mixed until uniform.

Example 2 – Aftersun Treatment lotion

30		%w/w
	Aqua	to 100
	Hydrated silica	5

- 12 -

	Isopropyl palmitate	4
	Arachidyl propionate	2
	Dimethicone	2
	Glycerin	2
5	Steareth-21	1.96
	Steareth-2	1.683
	Cetyl alcohol	1
	Tribehenin	1
	Glyceryl stearate	1
10	Paraffinum liquidum	0.994
	Panthenol	0.75
	Parfum	0.3
	Xanthan gum	0.3
	Sodium citrate	0.25
15	Tocopheryl acetate	0.2
	Hydroxyethylcellulose	0.1
	Bisabolol	0.095
	Citric acid	0.05
	Preservative	q.s
20	Magnesium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03

Method

25

Stage 1

The citric acid, sodium citrate and hydroxyethylcellulose are added to the water. Using a propellor stirrer, the mixture is stirred until dispersed. The xanthan gum is pre-dispersed in the glycerin and this is then added to the bulk, which is then heated to 70°C.

30

Stage 2

The isopropyl palmitate, arachidyl propionate, dimethicone, steareth-21, steareth-2, cetyl alcohol, tribehenin, glyceryl stearate, paraffinum liquidum are mixed and heated to 70°C to melt the waxes.

5

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and is mixed until emulsified and uniform. The emulsion is cooled to below 35°C using stirring.

Once below 35°C, the remaining materials are added, including the antioxidant complex. The product is made to weight using purified water, and mixed until uniform.

10

Example 3 – Anti-ageing Day Cream

15		%w/w
	Aqua	to 100
	Butylene glycol	5
	Dicaprylyl maleate	4
	Paraffinum liquidum	4
20	Octyl methoxycinnamate	3
	Petrolatum	3
	Cetyl Alcohol	2
	Glycerin	2
	Dimethicone	2
25	Cetearyl alcohol	1.6
	Butyl methoxydibenzoylmethane	1
	Hydroxyethylcellulose	0.4
	PEG-20 stearate	0.4
	Polyacrylamide	0.4
30	Parfum	0.3
	C13-14 isoparaffin	0.215
	Retinyl palmitate	0.1782

- 14 -

	Tetrasodium EDTA	0.1
	Citric acid	0.08
	Laureth-7	0.055
	BHT	0.0024
5	Sodium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03
	Preservative	q.s

10 Method

Stage 1

Tetrasodium EDTA and citric acid are added to the water using a propellor stirrer. The hydroxyethylcellulose is added and dispersed using a homogeniser.
15 butylene glycol, glycerin and methylparaben are added and the bulk is heated to 70°C.

Stage 2

The dicaprylyl maleate, paraffinum liquidum, octyl methoxycinnamate,
20 petrolatum, cetyl alcohol, dimethicone, cetearyl alcohol, butyl methoxydibenzoylmethane, PEG-20 stearate, C13-14 isoparaffin, laureth-7 and BHT are mixed and heated to 70°C to melt the waxes.

Stage 3

25 Using a homogeniser, stage 2 is added to stage 1 and the bulk is mixed until emulsified and stable. The product is then cooled to below 35°C using stirring. The remaining raw materials, including the antioxidant complex are added and the product is mixed using a propellor stirrer until uniform. The product is made to weight using purified water.

Example 4 – Anti-ageing Day Cream

		%w/w to 100
	Aqua	
5	Butylene glycol	5
	Dicaprylyl maleate	4
	Paraffinum liquidum	4
	Octyl methoxycinnamate	3
	Petrolatum	3
10	Cetyl Alcohol	2
	Glycerin	2
	Dimethicone	2
	Cetearyl alcohol	1.6
	Butyl methoxydibenzoylmethane	1
15	Hydroxyethylcellulose	0.4
	PEG-20 stearate	0.4
	Polyacrylamide	0.4
	Parfum	0.3
	C13-14 isoparaffin	0.215
20	Retinyl palmitate	0.1782
	Tetrasodium EDTA	0.1
	Citric acid	0.08
	Laureth-7	0.055
	BHT	0.0024
25	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03
	Preservative	q.s

Method

Stage 1

5 Tetrasodium EDTA and citric acid are added to the water using a propellor stirrer. The hydroxyethylcellulose is added and dispersed using a homogeniser. butylene glycol, glycerin and methylparaben are added and the bulk is heated to 70°C.

Stage 2

10 The dicaprylyl maleate, paraffinum liquidum, octyl methoxycinnamate, petrolatum, cetyl alcohol, dimethicone, cetearyl alcohol, butyl methoxydibenzoylmethane, PEG-20 stearate, C13-14 isoparaffin, laureth-7 and BHT are mixed and heated to 70°C to melt the waxes.

15 Stage 3

Using a homogeniser, stage 2 is added to stage 1 and the bulk is mixed until emulsified and stable. The product is then cooled to below 35°C using stirring. The remaining raw materials, including the antioxidant complex are added and the product is mixed using a propellor stirrer until uniform. The product is made
20 to weight using purified water.

Example 5 – Sun Protection Lotion SPF8

		%w/w
25	Aqua	to 100
	C12-15 Alkyl Benzoate	8
	Butylene glycol	5
	Butyl methoxydibenzoylmethane	2.2
	Dimethicone	2
30	Polyglyceryl-3 methylglucose distearate	2
	PVP/hexadecene copolymer	1.75
	Octyl methoxycinnamate	1.7

- 17 -

	Theobroma cacao	0.5
	Parfum	0.5
	Tocopheryl acetate	0.2
	Acrylates/vinyl isodecanoate crosspolymer	0.15
5	Potassium hydroxide	0.034
	Tetrasodium EDTA	0.02
	Preservative	q.s
	Sodium ascorbyl phosphate	0.15
	Morus alba	0.0023
10	Panax ginseng	0.03

Method

Stage 1

- 15 The EDTA is dispersed into the water. Using a propellor stirrer, the acrylates/vinyl isodecanoate crosspolymer are added and dispersed and hydrated. Butylene glycol is added and the aqueous phase is heated to 70°C.

Stage 2

- 20 The C12-15 alkyl benzoate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-3 methylglucose distearate, PVP/hexadecene copolymer, octyl methoxycinnamate, theobroma cacao and tocopheryl acetate are mixed and heated to 70°C to melt the waxes.

25 Stage 3

Using a homogeniser, stage 2 is added to stage 1 and the bulk is mixed until emulsified and uniform. The emulsion is cooled to below 35°C with stirring. The remaining materials, including the antioxidant complex are added and mixed. The product is made to weight using purified water and stirred until uniform.

Example 6 – Sun Protection Lotion SPF8

		%w/w
	Aqua	to 100
5	C12-15 Alkyl Benzoate	8
	Butylene glycol	5
	Butyl methoxydibenzoylmethane	2.2
	Dimethicone	2
	Polyglyceryl-3 methylglucose distearate	2
10	PVP/hexadecene copolymer	1.75
	Octyl methoxycinnamate	1.7
	Theobroma cacao	0.5
	Parfum	0.5
	Tocopheryl acetate	0.2
15	Acrylates/vinyl isodecanoate crosspolymer	0.15
	Potassium hydroxide	0.034
	Tetrasodium EDTA	0.02
	Preservative	q.s
	Magnesium ascorbyl phosphate	0.15
20	Morus alba	0.0023
	Panax ginseng	0.03

Method**25 Stage 1**

The EDTA is dispersed into the water. Using a propellor stirrer, the acrylates/vinyl isodecanoate crosspolymer are added and dispersed and hydrated. Butylene glycol is added and the aqueous phase is heated to 70°C.

30 Stage 2

The C12-15 alkyl benzoate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-3 methylglucose distearate, PVP/hexadecene copolymer, octyl

methoxycinnamate, theobroma cacao and tocopheryl acetate are mixed and heated to 70°C to melt the waxes.

Stage 3

- 5 Using a homogeniser, stage 2 is added to stage 1 and the bulk is mixed until emulsified and uniform. The emulsion is cooled to below 35°C with stirring. The remaining materials, including the antioxidant complex are added and mixed. The product is made to weight using purified water and stirred until uniform.

10 Example 7 – Aftersun Treatment

		%w/w
	Aqua	to 100
	Petrolatum	3
15	Cetyl Alcohol	2
	Dimethicone	2
	Glycerin	2
	Ceteath-20	1.7
	Paraffinum Liquidum	1
20	Sodium chloride	0.8
	Theobroma cacao	0.7
	Glyceryl stearate	0.5
	Parfum	0.3
	Allantoin	0.2
25	Hydroxyethylcellulose	0.1
	Triclosan	0.1
	Citric acid	0.02
	Preservative	q.s
	Sodium ascorbyl phosphate	0.15
30	Morus alba	0.0023
	Panax ginseng	0.03

- 20 -

Method

Stage 1

5 Into the water, sodium chloride and citric acid are added and dispersed. Using a propellor stirrer, hydroxyethylcellulose is added and dispersed. This phase is then heated to 70°C.

Stage 2

10 The petrolatum, cetyl alcohol, dimethicone, ceteath-20, paraffinum liquidum, theobroma cacao and glyceryl stearate are mixed and heated to 70°C to melt the waxes.

Stage 3

15 Using a homogeniser, stage 2 is added to stage 1, this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C with stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is made to weight using purified water and stirred until uniform.

20 Example 8 – Aftersun Treatment

	%w/w
Aqua	to 100
Petrolatum	3
25 Cetyl Alcohol	2
Dimethicone	2
Glycerin	2
Ceteath-20	1.7
Paraffinum Liquidum	1
30 Sodium chloride	0.8
Theobroma cacao	0.7
Glyceryl stearate	0.5

- 21 -

	Parfum	0.3
	Allantoin	0.2
	Hydroxyethylcellulose	0.1
	Triclosan	0.1
5	Citric acid	0.02
	Preservative	q.s
	Magnesium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03

10

Method

Stage 1

15 Into the water, sodium chloride and citric acid are added and dispersed. Using a propellor stirrer, hydroxyethylcellulose is added and dispersed. This phase is then heated to 70°C.

Stage 2

20 The petrolatum, cetyl alcohol, dimethicone, ceteath-20, paraffinum liquidum, theobroma cacao and glyceryl stearate are mixed and heated to 70°C to melt the waxes.

Stage 3

25 Using a homogeniser, stage 2 is added to stage 1, this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C with stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is made to weight using purified water and stirred until uniform.

Example 9 – Eye Contour Treatment Cream

		%w/w
	Aqua	to 100
5	Butylene glycol	6
	Paraffinum liquidum	5
	Octyl methoxycinnamate	4
	Dimethicone	2
	Petrolatum	2
10	Cetearyl octanoate	1.8
	Cetearyl alcohol	1.6
	Glyceryl stearate	1.5
	Cetyl alcohol	1
	Prunus dulcis	1
15	Glycerin	0.57
	Hydrogenated vegetable glycerides citrate	0.5
	Tocopheryl acetate	0.5
	Bisabolol	0.475
	Panthenol	0.45
20	Sodium phosphate	0.42
	PEG-20 stearate	0.4
	Isopropyl myristate	0.2
	Carbomer	0.15
	PEG-12 isostearate	0.125
25	Allantoin	0.1
	Tetrasodium EDTA	0.1
	Lactic acid	0.088
	Disodium phosphate	0.083
	Potassium hydroxide	0.051
30	Sodium ascorbyl phosphate	1.5
	Morus alba	0.023
	Panax ginseng	0.03

Preservative

q.s

Method

5 Stage 1

Into the water, citric acid, EDTA, sodium phosphate, disodium phosphate and lactic acid are added and dispersed. Using a homogeniser, carbomer is added and hydrated. The aqueous phase is then heated to 70°C.

10 Stage 2

The paraffinum liquidum, octyl methoxycinnamate, dimethicone, petrolatum, cetearyl octanoate, cetearyl alcohol, glyceryl stearate, cetyl alcohol, hydrogenated vegetable glycerides citrate, tocopheryl acetate, PEG-20 stearate, isopropyl myristate and PEG-12 isostearate are mixed and heated to
15 70°C to melt the waxes.

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using
20 stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 10 – Eye Contour Treatment Cream

25

	%w/w
Aqua	to 100
Butylene glycol	6
Paraffinum liquidum	5
30 Octyl methoxycinnamate	4
Dimethicone	2
Petrolatum	2

- 24 -

	Cetearyl octanoate	1.8
	Cetearyl alcohol	1.6
	Glyceryl stearate	1.5
	Cetyl alcohol	1
5	Prunus dulcis	1
	Glycerin	0.57
	Hydrogenated vegetable glycerides citrate	0.5
	Tocopheryl acetate	0.5
	Bisabolol	0.475
10	Panthenol	0.45
	Sodium phosphate	0.42
	PEG-20 stearate	0.4
	Isopropyl myristate	0.2
	Carbomer	0.15
15	PEG-12 isostearate	0.125
	Allantoin	0.1
	Tetrasodium EDTA	0.1
	Lactic acid	0.088
	Disodium phosphate	0.083
20	Potassium hydroxide	0.051
	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.023
	Panax ginseng	0.03
	Preservative	q.s

25

Method

Stage 1

- 30 Into the water, citric acid, EDTA, sodium phosphate, disodium phosphate and lactic acid are added and dispersed. Using a homogeniser, carbomer is added and hydrated. The aqueous phase is then heated to 70°C.

Stage 2

The paraffinum liquidum, octyl methoxycinnamate, dimethicone, petrolatum, cetearyl octanoate, cetearyl alcohol, glyceryl stearate, cetyl alcohol, hydrogenated vegetable glycerides citrate, tocopheryl acetate, PEG-20 stearate, isopropyl myristate and PEG-12 isostearate are mixed and heated to 70°C to melt the waxes.

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 11 – Skin Refreshing cream

	%w/w
Aqua	to 100
20 Butylene glycol	7.5
Silica	7.2
Arabinogalactan	5.35
Dimethicone	5.35
Petrolatum	5.35
25 Hydrated silica	3.75
Steareth-2	2.7
Prunus dulcis	2.7
Steareth-21	0.9
PVP/hexadecene copolymer	0.8
30 Carbomer	0.32
Sodium PCA	0.2
Parfum	0.2

- 26 -

	Hydroxyethylcellulose	0.16
	Potassium hydroxide	0.1
	Propylene glycol	0.1
	Magnesium ascorbyl phosphate	1.5
5	Morus alba	0.0023
	Panax ginseng	0.03
	Preservative	q.s

Method

10

Stage 1

Into the water, the carbomer is added and hydrated using a homogeniser. The aqueous phase is then heated to 70°C.

15

Stage 2

The silica, arabinogalactan, PVP/hexadecene copolymer, dimethicone, petrolatum, hydrated silica, steareth-2 and steareth-21 are mixed and heated to 70°C to melt the waxes.

20

Stage 3

25

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 12 – Daily Skin Protection Lotion

		%w/w
	Aqua	to 100
5	Dimethicone	5
	Glycerin	3
	Kaolin	3
	Dicaprylyl maleate	2.5
	Isopropyl myristate	2.5
10	Stearate-2	2
	Octyl methoxycinnamate	1
	Steareth-21	1
	Cetyl alcohol	0.75
	Butyl methoxydibenzoylmethane	0.5
15	Propylene glycol	0.5
	Hydroxyethylcellulose	0.4
	Xanthan gum	0.24
	Serica	0.1
	Sodium C8-16 isoalkylsuccinyl lactoglobulin sulfonate	0.1
20	Tetrasodium EDTA	0.1
	Citric acid	0.05
	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03
25	Preservative	q.s

Method**30 Stage 1**

Into the water, the citric acid and EDTA are added and dispersed. The hydroxyethylcellulose is added and hydrated using a propellor stirrer. Xanthan

gum is pre-dispersed in glycerin and added to the bulk. This is stirred until uniform. The aqueous phase is then heated to 70°C.

Stage 2

- 5 The dimethicone, dicaprylyl maleate, isopropyl myristate, stearate-2, octyl methoxycinnamate, steareth-21, cetyl alcohol and butyl methoxydibenzoylmethane are mixed and heated to 70 °C to melt the waxes.

Stage 3

- 10 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

15

Example 13 – anti-ageing Night Cream

		%w/w
	Aqua	to 100
20	Glycerin	5
	Paraffinum liquidum	4.5
	Dicaprylyl maleate	3
	Dimethicone	3
	Petrolatum	3
25	Paraffin	2.9
	Cetyl alcohol	2
	Steareth-2	2
	Glyceryl stearate	1.5
	Butyrospermum parkii	1.5
30	Steareth-21	1
	Mannitol	1
	Cera microcristallina	0.262

- 29 -

	Buxus chinensis	0.5
	Propylene glycol	0.48
	Parfum	0.4
	Borago officinalis	0.3
5	Hydroxyethylcellulose	0.3
	Lactis proteinum	0.3
	Xanthan gum	0.25
	Alcohol denat.	0.08
	Sodium citrate	0.08
10	Lecithin	0.075
	BHT	0.05
	Faex	0.04
	Phospholipids	0.03
	Citric acid	0.025
15	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03
	Preservative	q.s

20 Method

Stage 1

25 Into the water, the citric acid and sodium citrate are added and dispersed. The hydroxyethylcellulose is added and hydrated using a propellor stirrer. Xanthan gum is pre-dispersed in glycerin and added to the bulk. This is stirred until uniform. The aqueous phase is then heated to 70°C.

Stage 2

30 The paraffinum liquidum, dicaprylyl maleate, dimethicone, petrolatum, paraffin, cetyl alcohol, steareth-2, glyceryl stearate, steareth-21, cera microcristallina and BHT are mixed and heated to 70°C to melt the waxes.

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 14 – Sun protection Lotion for Sensitive Skin – SPF15

10		%w/w
	Aqua	to 100
	C12-15 alkyl benzoate	12
	Butylene glycol	5
	Octyl methoxycinnamate	3.8
15	Butyl methoxydibenzoylmethane	3
	Dimethicone	2
	Polyglyceryl-3 methylglucose distearate	2
	PVP/hexadecene copolymer	1.75
	C18-36 acid glycol ester	1.5
20	Polysorbate 60	0.5
	Titanium dioxide	0.3
	Tocopheryl acetate	0.2
	Acrylates/vinyl isodecanoate crosspolymer	0.14
	Potassium hydroxide	0.035
25	Tetrasodium EDTA	0.02
	Preservative	q.s
	Sodium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03
30	Method	

Stage 1

Into the water, citric acid is added and dispersed. The acrylates/vinyl isodecanoate crosspolymer are added and dispersed using a propellor stirrer. The aqueous phase is then heated to 70°C.

5

Stage 2

The C12-15 alkyl benzoate, PVP/hexadecene copolymer, octyl methoxycinnamate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-3 methylglucose distearate, C18-36 acid glycol ester, polysorbate 60, titanium dioxide and tocopheryl acetate are mixed and heated to 70°C to melt the waxes.

10

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

15

Example 15 – Sun protection Lotion for Sensitive Skin – SPF15

20

	%w/w
Aqua	to 100
C12-15 alkyl benzoate	12
Butylene glycol	5
25 Octyl methoxycinnamate	3.8
Butyl methoxydibenzoylmethane	3
Dimethicone	2
Polyglyceryl-3 methylglucose distearate	2
PVP/hexadecene copolymer	1.75
30 C18-36 acid glycol ester	1.5
Polysorbate 60	0.5
Titanium dioxide	0.3

- 32 -

	Tocopheryl acetate	0.2
	Acrylates/vinyl isodecanoate crosspolymer	0.14
	Potassium hydroxide	0.035
	Tetrasodium EDTA	0.02
5	Preservative	q.s
	Magnesium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03

10 Method

Stage 1

Into the water, citric acid is added and dispersed. The acrylates/vinyl isodecanoate crosspolymer are added and dispersed using a propellor stirrer.
15 The aqueous phase is then heated to 70°C.

Stage 2

The C12-15 alkyl benzoate, PVP/hexadecene copolymer, octyl methoxycinnamate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-
20 3 methylglucose distearate, C18-36 acid glycol ester, polysorbate 60, titanium dioxide and tocopheryl acetate are heated to 70°C to melt the waxes.

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until
25 emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 16 – Sun Protection Cream For Sensitive Skin

		%w/w
	Aqua	to 100
5	Octyl stearate	13.5
	Zinc oxide	13.5
	Isopropyl myristate	5
	Butylene glycol	3
	Isohexadecane	3
10	Titanium dioxide	2
	Polyglyceryl-3 oleate	1.75
	Cetyl dimethicone copolyol	1.35
	Magnesium sulfate	0.75
	Sodium chloride	0.75
15	Aluminium stearate	0.18
	Alumina	0.15
	Lecithin	0.13
	Isopropyl palmitate	0.05
	Sodium ascorbyl phosphate	0.15
20	Morus alba	0.0023
	Panax ginseng	0.03

Method**25 Stage 1**

Into the water, magnesium sulfate, sodium chloride and butylene glycol are added and dispersed. The aqueous phase is then heated to 70°C.

Stage 2

30 The octyl stearate, isopropyl myristate, isohexadecane, titanium dioxide, polyglyceryl-3 oleate, cetyl dimethicone copolyol, aluminium stearate, lecithin and isopropyl palmitate are mixed and heated to 70°C to melt the waxes.

Stage 3

Using a propellor stirrer, stage 2 is added to stage 1. Once uniform, the emulsion is transferred to a homogeniser and mixed to generate the viscosity. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 17 – Sun Protection Cream For Sensitive Skin

10

	%w/w
Aqua	to 100
Octyl stearate	13.5
Zinc oxide	13.5
15 Isopropyl myristate	5
Butylene glycol	3
Isohexadecane	3
Titanium dioxide	2
Polyglyceryl-3 oleate	1.75
20 Cetyl dimethicone copolyol	1.35
Magnesium sulfate	0.75
Sodium chloride	0.75
Aluminium stearate	0.18
Alumina	0.15
25 Lecithin	0.13
Isopropyl palmitate	0.05
Magnesium ascorbyl phosphate	0.15
Morus alba	0.0023
Panax ginseng	0.03

30

Method

Stage 1

Into the water, magnesium sulfate, sodium chloride and butylene glycol are added and dispersed. The aqueous phase is then heated to 70°C.

5 Stage 2

The octyl stearate, isopropyl myristate, isohexadecane, titanium dioxide, polyglyceryl-3 oleate, cetyl dimethicone copolyol, aluminium stearate, lecithin and isopropyl palmitate are mixed and heated to 70°C to melt the waxes.

10 Stage 3

Using a propellor stirrer, stage 2 is added to stage 1. Once uniform, the emulsion is transferred to a homogeniser and mixed to generate the viscosity. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 18 – Anti-ageing Foundation

		%w/w
20	Aqua	to 100
	Butylene glycol	9.8
	Cetearyl isononanoate	4.9
	Dimethicone	3.2
	Glycerin	1.96
25	Silica	1.9
	Caprylic/capric triglyceride	1.67
	Paraffinum liquidum	1.67
	Petrolatum	1.67
	Hydrogenated coco-glycerides	1.67
30	Cetearyl octanoate	1.5
	Cetearyl alcohol	1.35
	Octyl methoxycinnamate	1.28

- 36 -

	Talc	1
	Glyceryl stearate	0.95
	PEG-100 stearate	0.9
	Butyl methoxydibenzoylmethane	0.6
5	Saccharide isomerate	0.54
	Lactic acid	0.45
	Sodium polyacrylate	0.45
	Boron nitride	0.42
	Sodium PCA	0.4
10	Borago officinalis	0.4
	Tocopheryl acetate	0.4
	PVP/hexadecene copolymer	0.4
	PEG-20 stearate	0.33
	Glycolic acid	0.2
15	Sodium stearoyl lactylate	0.2
	Isopropyl myristate	0.17
	Polyaminopropyl biguanide	0.16
	Tetrasodium EDTA	0.1
	Xanthan gum	0.1
20	Citric acid	0.06
	Alcohol denat.	0.04
	Lecithin	0.037
	Preservative	q.s
	Rosmarinus officinalis	0.1
25	Morus alba	0.0023
	Panax ginseng	0.03

Method

30 Stage 1

Into the water, citric acid, EDTA and lactic acid are added and dispersed. Xanthan gum is pre-dispersed in butylene glycol and is added to the bulk. The

- 37 -

aqueous phase is then heated to 70°C.

Stage 2

5 The cetearyl isononanoate, dimethicone, silica, PVP/hexadecene copolymer, caprylic/capric triglyceride, paraffinum liquidum, petrolatum, hydrogenated coco-glycerides, cetearyl octanoate, cetearyl alcohol, octyl methoxycinnamate, talc, glyceryl stearate, PEG-100 stearate, butyl methoxydibenzoylmethane, borago officinalis, tocopheryl acetate, sodium stearyl lactylate, isopropyl myristate and lecithinoil phase are mixed and heated to 70°C to melt the waxes.

10

Stage 3

Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then
15 added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 19 – Anti-ageing Foundation

20		%w/w
	Aqua	to 100
	Butylene glycol	9.8
	Cetearyl isononanoate	4.9
	Dimethicone	3.2
25	Glycerin	1.96
	Silica	1.9
	Caprylic/capric triglyceride	1.67
	Paraffinum liquidum	1.67
	Petrolatum	1.67
30	Hydrogenated coco-glycerides	1.67
	Cetearyl octanoate	1.5
	Cetearyl alcohol	1.35

	Octyl methoxycinnamate	1.28
	Talc	1
	Glyceryl stearate	0.95
	PEG-100 stearate	0.9
5	Butyl methoxydibenzoylmethane	0.6
	Saccharide isomerate	0.54
	Lactic acid	0.45
	Sodium polyacrylate	0.45
	Boron nitride	0.42
10	Sodium PCA	0.4
	Borago officinalis	0.4
	Tocopheryl acetate	0.4
	PVP/hexadecene copolymer	0.4
	PEG-20 stearate	0.33
15	Glycolic acid	0.2
	Sodium stearyl lactylate	0.2
	Isopropyl myristate	0.17
	Polyaminopropyl biguanide	0.16
	Tetrasodium EDTA	0.1
20	Xanthan gum	0.1
	Citric acid	0.06
	Alcohol denat.	0.04
	Lecithin	0.037
	Preservative	q.s
25	Origanum vulgare	0.1
	Morus alba	0.0023
	Panax ginseng	0.03

Method

30

Stage 1

Into the water, citric acid, EDTA and Lactic acid are added and dispersed.

Xanthan gum is pre-dispersed in butylene glycol and is added to the bulk. The aqueous phase is then heated to 70°C.

Stage 2

5 The cetearyl isononanoate, dimethicone, Silica, PVP/hexadecene copolymer, caprylic/capric triglyceride, paraffinum liquidum, petrolatum, hydrogenated coco-glycerides, cetearyl octanoate, cetearyl alcohol, octyl methoxycinnamate, talc, glyceryl stearate, PEG-100 stearate, butyl methoxydibenzoylmethane, borago
10 officinalis, tocopheryl acetate, sodium stearyl lactylate, isopropyl myristate and lecithinoil phase are mixed and heated to 70°C to melt the waxes.

Stage 3

15 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

20 Example 20 – Sun Protection Spray – SPF15

	%w/w
Aqua	to 100
Dicaprylyl maleate	12
25 Butylene glycol	5
Octyl methoxycinnamate	4
Butyl methoxydibenzoylmethane	3.5
Dimethicone	3
Polyglyceryl-3 methylglucose distearate	3
30 Acrylates/octylacrylamide copolymer	2
C18-36 acid glycol ester	1.5
Triethanolamine	0.5

	Tocopheryl acetate	0.2
	Acrylates/vinyl isodecanoate crosspolymer	0.05
	Tetrasodium EDTA	0.02
	Potassium hydroxide	0.015
5	Preservative	q.s
	Sodium ascorbyl phosphate	0.15
	Morus alba	0.0023
	Panax ginseng	0.03

10 Method

Stage 1

15 Into the water, EDTA is added and dispersed. Acrylates/vinyl isodecanoate crosspolymer are added and dispersed using a propellor stirrer. Butylene glycol is added and dispersed. The aqueous phase is then heated to 70°C.

Stage 2

20 The dicaprylyl maleate, Acrylates/octylacrylamide copolymer, octyl methoxycinnamate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-3 methylglucose, C18-36 acid glycol ester and tocopheryl acetate are mixed and heated to 80°C to melt the waxes.

Stage 3

25 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 21 – Sun Protection Spray – SPF15

		%w/w
	Aqua	to 100
5	Dicaprylyl maleate	12
	Butylene glycol	5
	Octyl methoxycinnamate	4
	Butyl methoxydibenzoylmethane	3.5
	Dimethicone	3
10	Polyglyceryl-3 methylglucose distearate	3
	Acrylates/octylacrylamide copolymer	2
	C18-36 acid glycol ester	1.5
	Triethanolamine	0.5
	Tocopheryl acetate	0.2
15	Acrylates/vinyl isodecanoate crosspolymer	0.05
	Tetrasodium EDTA	0.02
	Potassium hydroxide	0.015
	Preservative	q.s
	Magnesium ascorbyl phosphate	0.15
20	Morus alba	0.0023
	Panax ginseng	0.03

Method**25 Stage 1**

Into the water, EDTA is added and dispersed. Acrylates/vinyl isodecanoate crosspolymer are added and dispersed using a propellor stirrer. Butylene glycol is added and dispersed. The aqueous phase is then heated to 70°C.

30 Stage 2

The dicaprylyl maleate, Acrylates/octylacrylamide copolymer, octyl methoxycinnamate, butyl methoxydibenzoylmethane, dimethicone, polyglyceryl-

3 methylglucose, C18-36 acid glycol ester and tocopheryl acetate are mixed and heated to 70°C to melt the waxes.

Stage 3

5 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

10

Example 22 – Toner & Cleanser 2 In 1

		%w/w
	Alcohol denat.	48
15	Aqua	to 100
	PEG-8	6
	Glycerin	2
	Propylene glycol	0.5
	Sodium C8-16 isoalkylsuccinyl lactoglobulin sulfonate	0.02
20	Laminaria saccharina	0.01
	Hamamelis virginiana	0.006
	Citrullus vulgaris	0.001
	Preservative	q.s
	Sodium ascorbyl phosphate	1.5
25	Morus alba	0.0023
	Panax ginseng	0.03

Method

30

Stage 1

Into the water, alcohol denat. is added and dispersed until uniform. Using a propellor stirrer, all materials including the antioxidant complex, are slowly

added and stirred until uniform. The product is made to weight using purified water and stirred until uniform.

Example 23 – Toner & Cleanser 2 In 1

5		%w/w
	Alcohol denat.	48
	Aqua	to 100
	PEG-8	6
	Glycerin	2
10	Propylene glycol	0.5
	Sodium C8-16 isoalkylsuccinyl lactoglobulin sulfonate	0.02
	Laminaria saccharina	0.01
	Hamamelis virginiana	0.006
	Citrullus vulgaris	0.001
15	Preservative	q.s
	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03

20 **Method**

Stage 1

Into the water, alcohol denat. Is added and dispersed until uniform. Using a propellor stirrer, all materials including the antioxidant complex, are slowly
25 added and stirred until uniform. The product is made to weight using purified water and stirred until uniform.

Example 24 – Skin pH Balancing Toner

30		%w/w
	Aqua	to 100
	Alcohol denat.	7.9

- 44 -

	Butylene glycol	2
	Dimethicone copolyol	1.5
	Sodium lactate	0.6
	Glycerin	0.5
5	Allantoin	0.1
	Propylene glycol	0.1
	Lactic acid	0.002
	Preservative	q.s
	Sodium ascorbyl phosphate	1.5
10	Morus alba	0.0023
	Panax ginseng	0.03

Method

15 Stage 1

Into the water, lactic acid and alcohol denat are separately added and dispersed until uniform. Using a propellor stirrer, all materials including the antioxidant complex, are slowly added and stirred until uniform. The product is made to weight using purified water and stirred until uniform.

20

Example 25 – Skin pH Balancing Toner

		%w/w
	Aqua	to 100
25	Alcohol denat.	7.9
	Butylene glycol	2
	Dimethicone copolyol	1.5
	Sodium lactate	0.6
	Glycerin	0.5
30	Allantoin	0.1
	Propylene glycol	0.1
	Lactic acid	0.002

- 45 -

Preservative	q.s
Magnesium ascorbyl phosphate	1.5
Morus alba	0.0023
Panax ginseng	0.03

5

Method

Stage 1

10 Into the water, lactic acid and alcohol denat are separately added and dispersed until uniform. Using a propellor stirrer, all materials including the antioxidant complex, are slowly added and stirred until uniform. The product is made to weight using purified water and stirred until uniform.

Example 26 pH Balanced Cleansing Lotion

15

	%w/w
Aqua	to 100
Paraffinum liquidum	14
Isopropyl palmitate	7
20 Glyceryl stearate	2.5
PEG-100 stearate	2.5
Butylene glycol	2
Hydrogenated vegetable glycerides citrate	2
Polysorbate 60	0.5
25 Sorbitan stearate	0.5
Persea gratissima	0.3
Prunus persica	0.3
Propylene glycol	0.3
Acrylates/C10-30 alkyl acrylate crosspolymer	0.12
30 Potassium hydroxide	0.05
Tetrasodium EDTA	0.02
Medicago sativa	0.0045

Preservative	q.s
Sodium ascorbyl phosphate	1.5
Morus alba	0.023
Panax ginseng	0.03

5

Method

Stage 1

10 Into the water, EDTA is added and dispersed. Butylene glycol is then added and dispersed. The aqueous phase is then heated to 70°C.

Stage 2

15 The paraffinum liquidum, isopropyl palmitate, glyceryl stearate, PEG-100 stearate, hydrogenated vegetable glycerides citrate, polysorbate 60 and sorbitan stearate are mixed and heated to 70°C to melt the waxes.

Stage 3

20 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 27 pH Balanced Cleansing Lotion

25

	%w/w
Aqua	to 100
Paraffinum liquidum	14
Isopropyl palmitate	7
30 Glyceryl stearate	2.5
PEG-100 stearate	2.5
Butylene glycol	2

	Hydrogenated vegetable glycerides citrate	2
	Polysorbate 60	0.5
	Sorbitan stearate	0.5
	Persea gratissima	0.3
5	Prunus persica	0.3
	Propylene glycol	0.3
	Acrylates/C10-30 alkyl acrylate crosspolymer	0.12
	Potassium hydroxide	0.05
	Tetrasodium EDTA	0.02
10	Medicago sativa	0.0045
	Preservative	q.s
	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.023
	Panax ginseng	0.03

15

Method

Stage 1

20 Into the water, EDTA is added and dispersed. Butylene glycol is then added and dispersed. The aqueous phase is then heated to 70°C.

Stage 2

25 The paraffinum liquidum, isopropyl palmitate, glyceryl stearate, PEG-100 stearate, hydrogenated vegetable glycerides citrate, polysorbate 60 and sorbitan stearate are mixed and heated to 70°C to melt the waxes.

Stage 3

30 Using a homogeniser, stage 2 is added to stage 1 and this is mixed until emulsified and uniform. The emulsion is then cooled to below 35°C using stirring. The remaining materials, including the antioxidant complex are then added and mixed. The product is then made to weight using purified water and is stirred until uniform.

Example 28 - Lipstick

		% w/w
	Ricinus communis	20
5	Octyldodecanol	15
	Pentaerythrityl tetracaprylate/caprate	14
	Mica	10
	Bis-diglyceryl caprylate/caprate/isostearate/ Stearate/hydroxystearate adipate	7.5
10	Paraffin	5
	Cera microcristallina	5
	Propylene glycol	2
	Hydrogenated castor oil	2
	Candelilla cera	1
15	Camauba	1
	Synthetic wax	1
	Butyrospermum parkii	1
	Titanium dioxide	0.5
	Tocopheryl acetate	0.2
20	Polyquaternium-37	0.2
	Red colour	q.s
	Magnesium ascorbyl phosphate	1.5
	Morus alba	0.0023
	Panax ginseng	0.03

25

Method**Stage 1**

The antioxidant complex is pre-dispersed in propylene glycol, with stirring.

30

Stage 2

The remaining materials are mixed in a vessel and heated to 85°C until melted and uniform. The product is cooled and the antioxidant complex pre-mix is added below 70°C. The product poured into a suitable container and allowed to cool to room temperature to set.

Example 29 - Lipstick

		% w/w
10	Ricinus communis	20
	Octyldodecanol	15
	Pentaerythrityl tetracaprylate/caprate	14
	Mica	10
	Bis-diglyceryl caprylate/caprate/isostearate/	
15	Stearate/hydroxystearate adipate	7.5
	Paraffin	5
	Cera microcristallina	5
	Propylene glycol	2
	Hydrogenated castor oil	2
20	Candelilla cera	1
	Carnauba	1
	Synthetic wax	1
	Butyrospermum parkii	1
	Titanium dioxide	0.5
25	Tocopheryl acetate	0.2
	Polyquaternium-37	0.2
	Red colour	q.s
	Sodium ascorbyl phosphate	1.5
	Morus alba	0.0023
30	Panax ginseng	0.03

Method

Stage 1

The antioxidant complex is pre-dispersed in propylene glycol, with stirring.

5

Stage 2

The remaining materials are mixed in a vessel and heated to 85°C until melted and uniform. The product is cooled and the antioxidant complex pre-mix is added below 70°C. The product poured into a suitable container and allowed to cool to room temperature to set.

10

A number of trials were conducted to demonstrate the efficacy of the synergistic combinations of antioxidant agents.

15

In Vitro Tests

The following procedure tests the ability of antioxidants to protect lipids from the damaging effects of UV light. The antioxidants to be tested are morus alba ("Mulberry Concentrate" from Aston Chemicals), magnesium ascorbyl phosphate and panax ginseng ("Phytexcell Panax ginseng" from Croda Chemicals Ltd). The antioxidants were tested individually at a particular concentration and in combination. In the test the antioxidant or combination of antioxidants is mixed with a known skin lipid (linoleic acid) and irradiated using UV light. The quantity of peroxides in each sample is measured colourimetrically after irradiation to assess the level of damage caused by peroxidation of the linoleic acid.

20

25

30

A 1% lipid stock solution is prepared dissolving linoleic acid in an aqueous solution of octoxynol-9 (Triton X-100). Stock solutions in aqueous TBS buffer of the following antioxidants magnesium ascorbyl phosphate, morus alba and panax ginseng were prepared at 15%, 1.0% and 1.0% respectively. In experiments where the antioxidants were tested individually, 25µl of the lipid

stock is vortexed in an ependorf together with 5µl of the antioxidant solution and 20µl of Triton X~100 (mixture of water and detergent used to dissolve the lipid). In experiments where the antioxidants were tested in combination, 25µl of the lipid stock is vortexed in an ependorf together with 5µl of each of the antioxidant solutions and 10µl of Triton X100. The final concentration of the lipid is 0.5% and of the antioxidants is 1.5%, 0.1% and 0.1% respectively.

The control sample used in the experiment is a combination of 25µl of the lipid stock solution and 25µl of TritonX100 and water. This solution contains no antioxidants. Samples of this control were taken before irradiation to act as untreated controls.

Using a micropipette plate 7.5µl of each sample is pipetted into 3 wells, i.e. in triplicate, and irradiated with UV light for 40 minutes. After irradiation an assay called the lipid peroxidation assay is carried out. This determines the amount of peroxides in each well. The reaction that occurs causes a colour change from colourless to blue which is measured colourimetrically at 675nm. The more peroxides present the darker the blue colouration and the higher the observed absorbance.

The results showed that the amount of peroxidation present in the samples treated with the antioxidants individually is similar to that observed when no antioxidants were present whereas no peroxidation is observed when the combination of antioxidants is used. The results are shown in Table 1 below.

The final column shows the percentage of peroxidation observed when compared to that seen with the irradiated controls.

Table 1

UV minutes	Antioxidant	Concentration	Absorbance	
0			0	0
40			0.7367	100
40	Magnesium ascorbyl phosphate	1.50%	0.84	>100
40	Panax ginseng	0.10%	0.838	>100
40	Morus alba	0.10%	0.833	>100
40	Combination	1.70%	-0.119	0

- 5 No protection is seen when using the antioxidants on their own, however when in combination we see a maximum effect i.e. complete lipid protection. This is greater than the additive effect of each individual antioxidant indicating a synergistic relationship between them.

In Vivo Tests

- 10 Test formulations containing antioxidants and control formulations containing no antioxidants were applied to the skin of the forearm of volunteers. An adhesive disc is applied to the skin to sample skin cells and the disc is then irradiated with broad spectrum UVA/B to induce oxidation of the lipid. Following extraction of the lipid into methanol, the degree of lipid hydroperoxides (free radical generated damage) formed were measured colourimetrically. The degree of protection afforded by the antioxidants is thus measured and compared to unirradiated and irradiated controls.

- 20 The composition of Example 4 was given to volunteers who were instructed to use it daily on their face. The volunteers were then asked to assess how their skin felt. The skin of the volunteers noted an improvement in how moisturised

5 their skin looked and the experts also noted improvements in skin softness and smoothness. Further improvement in the moisturised appearance of the skin was noted by the experts after 8 weeks. After 12 weeks use the experts noted that the skin of the users looked more fresh and healthy and profilometry measurements showed that the depth of fine lines and wrinkles in the skin had been reduced.

CLAIMS

1. Topical cosmetic compositions for application to the skin comprising a
5 suitable diluent or carrier in combination with a synergistic mixture of three anti-free-radical agents selected from
- (a) ascorbic acid, its salts, esters, glucosides and glucosamines;
(b) tocopherol and its esters; and
10 (c) herbal extracts selected from ginkgo biloba, morus alba, organum vulgare, panax ginseng, rosmarinus officinalis, birch extract, camellia sinensis, acerola cherry powder and grape seed oil.
2. Topical compositions as claimed in claim 1 wherein the esters of
15 ascorbic acid are sodium ascorbyl phosphate, magnesium ascorbyl phosphate, magnesium ascorbyl phosphate or magnesium ascorbyl palmitate.
3. Topical compositions as claimed in claim 1 or claim 2 wherein the ester of
20 tocopherol is tocopherol acetate.
4. Topical compositions as claimed in any one of claims 1 to 3 wherein the
total amount of anti-free-radical agents present lies in the range 0.001 to 10%
by weight.
- 25 5. Topical compositions as claimed in any preceding claim wherein the total
amount of anti-free-radical agents present lies in the range 0.5 to 5% by weight.
6. Topical compositions as claimed in any preceding claim wherein the total
amount of anti-free-radical agents present lies in the range 1 to 2% by weight.
30
7. Topical compositions as claimed in any preceding claims where the
synergistic combination of anti-free-radicals comprises (a) panax ginseng, (b)
morus alba and (c) magnesium ascorbyl phosphate, sodium ascorbyl
phosphate, rosmarinus officinalis or organum vulgare.
35
8. Topical compositions as claimed in claim 7 wherein (a) panax ginseng is
present in an amount of 0.005 to 0.1% by weight of the composition; (b) the

5 morus alba is present in an amount of 0.0005 to 0.01% by weight of the composition; (c) the sodium or magnesium ascorbyl phosphate is present in an amount from 0.05 to 2.5% by weight of the composition; and (d) the rosmarinus officinalis or organum vulgare is present in an amount of 0.01 to 0.1% by weight of the composition.

10 9. Topical compositions as claimed in claim 7 wherein panax ginseng is present in an amount of 0.01 to 0.05% by weight of the composition; (b) the morus alba is present in an amount of 0.001 to 0.005% by weight of the composition; (c) the sodium or magnesium ascorbyl phosphate is present in an amount from 0.1 to 2% by weight of the composition; and (d) the rosmarinus officinalis or organum vulgare is present in an amount of 0.05 to 0.2% by weight of the composition.

15 10. Topical compositions as claimed in claim 7 wherein (a) panax ginseng is present in an amount of about 0.03% by weight of the composition; (b) the morus alba is present in an amount of about 0.0023% by weight of the composition; (c) the sodium or magnesium ascorbyl phosphate is present in an amount from 0.15 to 1.5% by weight of the composition; and (d) the rosmarinus
20 officinalis or organum vulgare is present in an amount of about 0.1% by weight of the composition.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P/695	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/ 08729	International filing date (day/month/year) 07/09/2000	(Earliest) Priority Date (day/month/year) 09/09/1999
Applicant THE BOOTS COMPANY PLC		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

SKINCARE COMPOSITION AGAINST FREE RADICALS

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

Topical cosmetic compositions for application to the skin comprises a suitable diluent or carrier in combination with a synergistic mixture of three anti-free-radical agents selected from

ascorbic acid, its salts, esters, glucosides and glucosamines;

tocopherol and its esters;

herbal extracts selected from ginkgo biloba, morus alba, origanum vulgare, panax ginseng, rosmarinus officinalis, birch extract, camellia sinensis, acerola cherry powder and grape seed oil.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08729

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, FSTA, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199840 Derwent Publications Ltd., London, GB; Class B02, AN 1998-463113 XP002156754 "Antioxidant - contains rosemary extract, tocopherol concentrate and higher fatty acid ascorbate" & JP 10 195434 A (LION CORP), 28 July 1998 (1998-07-28) abstract</p>	1
X	<p>WO 99 33439 A (ROBERTS RICHARD L ;GREENE JAMES A (US); SHAKLEE CORP (US); SIDDIQU) 8 July 1999 (1999-07-08) examples page 6, line 3 - line 18</p>	1-10

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

9 January 2001

Date of mailing of the international search report

19/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040. Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Bendl, E

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PC 00/08729

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 084 289 A (SHIN HYUN-KYUNG ET AL) 28 January 1992 (1992-01-28)	1-10
Y	column 2, line 7 - line 31 -----	1-10
E	WO 00 64278 A (CHEN JAU FEI) 2 November 2000 (2000-11-02) example 7 -----	1-10
Y	WO 98 33494 A (KOSBAB JOHN V) 6 August 1998 (1998-08-06) page 5; example IE -----	1-10
Y	US 5 314 686 A (TODD JR PAUL H) 24 May 1994 (1994-05-24) column 12, line 41 - line 43 -----	1-10

INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/JP 00/08729

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
JP 10195434	A	28-07-1998	NONE		
WO 9933439	A	08-07-1999	US	6036946 A	14-03-2000
			US	6015548 A	18-01-2000
			AU	1944599 A	19-07-1999
			EP	1047392 A	02-11-2000
US 5084289	A	28-01-1992	KR	9104884 B	15-07-1991
			JP	2588784 B	12-03-1997
			JP	3197595 A	28-08-1991
WO 0064278	A	02-11-2000	WO	0064279 A	02-11-2000
WO 9833494	A	06-08-1998	AU	6141498 A	25-08-1998
			EP	1021177 A	26-07-2000
US 5314686	A	24-05-1994	US	5230836 A	27-07-1993
			AT	196979 T	15-11-2000
			CA	2071415 A	21-12-1992
			DE	69231521 D	23-11-2000
			EP	0590029 A	06-04-1994
			JP	6508748 T	06-10-1994
			WO	9300015 A	07-01-1993
			US	5290481 A	01-03-1994
			US	5296249 A	22-03-1994